Abstract
<h3>To the Editor.—</h3> Reporting from a workshop at the National Institutes of Health, Bethesda, Md,<sup>1</sup>Mr Marwick stated that "the large Swedish field trial of two acellular pertussis vaccines<sup>2</sup>has not shown levels of efficacy high enough to make either vaccine a likely candidatefor immediate licensure in the United States." We can now report efficacy data from continued surveillance during the posttrial period Aug 27, 1987, to March 20, 1988, to elucidate protection over time and to discuss the effect of surveillance techniques on observed efficacy estimates. All laboratory-confirmed cases of pertussis among children born between March 1985 and September 1985 who participated in the efficacy trial have been identified from laboratory reports to the National Bacteriological Laboratory, Stockholm, and also from spontaneous parental reporting. Study nurses have interviewed parents about the course of illness using questions similar to those used in the main study. The parents
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
